Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros

Banco de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
J Obstet Gynaecol ; 42(6): 2008-2012, 2022 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-35653773

RESUMEN

In this study, we aimed to assess the determining role of foetal fibronectin (FFN) and plasminogen activator inhibitor type (PAI-1) levels in the antenatal prediction of placenta accreta spectrum in cases with risk factors for placenta accreta spectrum. Singleton live pregnancies with placenta previa or low-lying placenta within 32-34 weeks of gestation were included in the study. The cases were divided into two groups after delivery as those with PAS and those with normal placentation. 54 cases diagnosed with placenta previa or low-lying placenta were included in the study. 17 of the cases underwent peripartum hysterectomy due to placenta accreta spectrum. 37 cases with normal placentation underwent caesarean delivery. Foetal fibronectin (p:.03) and PAI-1 (p:.02) levels were determined to be significantly different between cases with placenta accreta spectrum and cases with normal placentation. AUC for foetal FFN was calculated to be 0.69, while the AUC for, PAI-1was 0.66. Results for both FFN and PAI-1 were not found useful enough for the diagnosis of PAS. IMPACT STATEMENTWhat is already known on this subject? We lack biomarkers which can identify placenta accreta spectrum.What do the results of this study add? Maternal plasma levels of FFN and PAI-1 significantly altered in PASWhat are the implications of these findings for clinical practice and/or future research? If multiple of median values of FFN and PAI-1 levels in maternal blood are determined in future studies, it can be used in the antenatal diagnosis of PAS cases.


Asunto(s)
Placenta Accreta , Placenta Previa , Biomarcadores , Femenino , Fibronectinas , Humanos , Histerectomía , Placenta Accreta/diagnóstico , Placenta Previa/diagnóstico , Placentación , Inhibidor 1 de Activador Plasminogénico , Inactivadores Plasminogénicos , Embarazo , Estudios Retrospectivos
2.
J Adolesc Young Adult Oncol ; 10(3): 355-358, 2021 06.
Artículo en Inglés | MEDLINE | ID: mdl-33835857

RESUMEN

Choriocarcinoma is an aggressive malignant trophoblastic neoplasm. The rapid growth of neoplastic tissue and myometrial invasion can cause uterine perforation. It is important to quickly diagnose the disease and plan treatment because these tumors are nearly always curable, and fertility can be preserved in most cases with proper management. The outbreak of novel coronavirus disease has affected the whole world since January 2019 and caused delays in treatment and follow-up of patients all over the world. In this study, we report a case of choriocarcinoma who postponed her admission to the hospital after diagnosis because she was afraid of the pandemic and lost her fertility due to uterine rupture and massive intra-abdominal hemorrhage.


Asunto(s)
COVID-19 , Coriocarcinoma/complicaciones , Refugiados , Tiempo de Tratamiento , Hemorragia Uterina/etiología , Neoplasias Uterinas/complicaciones , Rotura Uterina/etiología , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , COVID-19/epidemiología , Quimioterapia Adyuvante , Coriocarcinoma/tratamiento farmacológico , Coriocarcinoma/cirugía , Femenino , Humanos , Histerectomía , Pandemias , SARS-CoV-2 , Hemorragia Uterina/cirugía , Neoplasias Uterinas/tratamiento farmacológico , Neoplasias Uterinas/cirugía , Rotura Uterina/cirugía , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA